Mineralys Therapeutics Cash Flow Statement
NASDAQ: MLYSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
23.37+0.99 (+4.42%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mineralys Therapeutics free cash flow
In fiscal 2025, Mineralys Therapeutics generated -$142.4 million of operating cash flow and spent $15,000 on capital expenditures. That left free cash flow of -$142.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
Mineralys Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 |
|---|---|---|---|---|
| Net Income | -154.65M | -177.81M | -71.90M | -29.80M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 59.00K | 43.00K | 0 | — |
| Stock-Based Compensation | 19.32M | 11.34M | 5.06M | 455.00K |
| Change in Working Capital | 2.90M | 9.10M | -7.12M | 772.00K |
| Operating Cash Flow | -142.42M | -166.31M | -81.17M | -29.22M |
| Capital Expenditures | -15.00K | -96.00K | 0 | — |
| Investing Cash Flow | -389.75M | 114.96M | -160.47M | -21.76M |
| Financing Cash Flow | 591.00M | 116.14M | 203.25M | 128.02M |
| Net Change in Cash | 58.83M | 64.79M | -38.40M | 77.04M |
| Free Cash Flow | -142.43M | -166.41M | -81.17M | -29.22M |
This table shows 4 annual periods of Mineralys Therapeutics's cash flow statement, from FY 2025 back to FY 2022, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MLYS's reporting calendar. What is a cash flow statement?